Federal Bipartisan Effort Seeks to Reschedule Psychedelic Breakthrough Therapies
Federal lawmakers – from both sides of the aisle and in both Congressional bodies – are pushing for a means of streamlining so-called “breakthrough therapies” that involve psychedelic drugs like MDMA and psilocybin for the purpose of promoting drug research and development.
As longtime Los Angeles cannabis business attorneys, we help break down what legislators are after.
The new bill, introduced by Democrats and Republicans in both the House and Senate, is titled the, “Breakthrough Therapies Act.” It seeks to revise the U.S. Controlled Substances Act by establishing a procedure through which certain Schedule I narcotics can be considered “therapies” by the U.S. food & Drug Administration. Either that, or they could qualify for a waiver via the U.S. food, Drug, and Cosmetic Act (FDCA). This waiver would allow the drugs to be transferred under a lower-schedule classification to research facilities and pharmaceutical laboratories.